8-K: AEON Biopharma Announces CEO Transition: Marc Forth Steps Down, Jost Fischer Appointed Interim CEO

AEON Biopharma announces that Marc Forth is stepping down as President and CEO, with Jost Fischer, Chairman of the Board, appointed as Interim CEO, effective April 4, 2025.

Summary

• AEON Biopharma announced that Marc Forth will resign as President and CEO, effective April 4, 2025, to pursue another opportunity but will remain on the Board of Directors.
• Jost Fischer, the current Chairman of the Board, has been appointed as Interim CEO while the Board seeks a permanent replacement.
• The company is focused on developing ABP-450, a botulinum toxin complex, for therapeutic indications.
• AEON anticipates a Biosimilar BPD Type 2a meeting with the FDA in the second half of 2025 and believes its current cash balance is sufficient to work through this meeting.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While a CEO transition introduces uncertainty, the company has appointed an experienced Interim CEO and is progressing with its key development program. The company also believes its current cash balance will allow it to work through its Biosimilar BPD Type 2a meeting with FDA anticipated in the second half of 2025.

Positives

• Marc Forth will remain on the Board of Directors to provide strategic guidance.
• Jost Fischer's extensive experience makes him qualified to serve as Interim CEO.
• The company is making steady progress along a 351(k) biosimilar regulatory pathway.
• AEON has a Biosimilar BPD Type 2a meeting with the FDA anticipated in the second half of 2025.
• The company believes its current cash balance will allow it to work through the Biosimilar BPD Type 2a meeting with the FDA.

Negatives

• The departure of the CEO creates uncertainty in leadership.
• The company is currently searching for a permanent CEO.

Risks

• The company's future success depends on the outcome of regulatory meetings and the development of ABP-450.
• The company's ability to raise financing in the future is a risk factor.
• The company's ability to maintain the cash balance required to work through the Biosimilar BPD Type 2a meeting with the FDA is a risk factor.
• The company's ability to continue to meet continued stock exchange listing standards is a risk factor.

Future Outlook

The company anticipates a Biosimilar BPD Type 2a meeting with the FDA in the second half of 2025 and will announce the results and next steps in their development program.

Management Comments

• 'I want to thank Marc for his invaluable contributions to AEON over the last several years and his dedication to exhaustively evaluating all opportunities for the Company to execute its growth strategy,' commented Mr. Fischer.
• Mr. Fischer stated that the company is making steady progress along a 351(k) biosimilar regulatory pathway that could allow it to bring ABP-450 to the U.S. market for all of BOTOX's currently approved and future therapeutic indications under a single FDA approval.
• Mr. Fischer stated that he looks forward to working with the AEON team and the Board to ensure their program for ABP-450 continues to move forward without delay.
• Mr. Fischer stated that the company believes its current cash balance will allow it to work through their Biosimilar BPD Type 2a meeting with FDA anticipated in the second half of 2025.

Industry Context

The announcement comes as AEON Biopharma is focused on developing ABP-450 as a biosimilar to Botox, a competitive market with significant potential.

Comparison to Industry Standards

• Evolus markets a botulinum toxin complex called Jeuveau, which is the same as AEON's ABP-450, but for cosmetic indications.
• AEON is pursuing a 351(k) biosimilar pathway, similar to other companies developing biosimilars to established biologics.
• Daewoong manufactures ABP-450, and its facility has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency, which is a standard requirement for biopharmaceutical manufacturing.

Management Changes

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the CEO transition.
• Employees may experience changes in leadership and direction.
• Customers and suppliers may not be immediately impacted, but the long-term success of ABP-450 is important to them.
• Creditors will be interested in the company's financial stability and ability to continue operations.

Next Steps

• The Board will continue to search for a permanent CEO.
• The company will proceed with its Biosimilar BPD Type 2a meeting with the FDA in the second half of 2025.
• The company will announce the results of the meeting with the FDA and next steps in its development program.

Key Dates

Keywords

AEON Biopharma, CEO transition, Marc Forth, Jost Fischer, ABP-450, Biosimilar, FDA, Botulinum toxin, Therapeutic indications